SPRB Stock Summary and Trading Ideas (Spruce Biosciences | NASDAQ:SPRB)

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.

Spruce Biosciences trades on the NASDAQ stock market under the symbol SPRB.

As of July 21, 2026, SPRB stock price climbed to $45.86 with 22,209 million shares trading.

SPRB has a beta of -7.02, meaning it tends to be less sensitive to market movements. SPRB has a correlation of 0.07 to the broad based SPY ETF.

SPRB has a market cap of $126.22 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that SPRB belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.

SPRB support price is $42.48 and resistance is $46.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRB shares will trade within this expected range on the day.